Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06805825 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites revised (5)v8
  2. Site contacts updated at 1 of 5 sitesv7
  3. Study sites: 3 to 5v6
  4. Study sites: 2 to 3v5
  5. Study sites: 1 to 2v4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 28, 2025 to Feb 3, 2025
    • Site details revised
    v3
  2. Study sites: 0 to 1v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novelty Nobility, Inc.
1 trial monitored
See all monitored trials
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Melanoma
1,092 trials monitored
See 60 trials at risk
Kidney Cancer
889 trials monitored
See 68 trials at risk
and 1 more disease
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
Trial Details
NCT Number NCT06805825
Lead Sponsor Novelty Nobility, Inc.
Conditions
(from sponsor)		 Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma, Neuroendocrine Tumors, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Related terms Carcinoma, Adenoid Cystic, Carcinoma, Renal Cell, Gastrointestinal Stromal Tumors, Neuroendocrine Tumors, Piebaldism, Small Cell Lung Carcinoma, Uveal Melanoma
Enrollment 67 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov